Searched for
EXELAN
ETPWLA 2023: Presenting the shortlisted nominees for the Business Leader of the Year AwardAhead of the Grand Finale of the ETPrime Women Leadership Awards (ETPWLA) 2023, the Economic Times takes immense pride in showcasing the no...- Pills to wellness, Cipla is seeking a new identityOne of the major successes of Hamied was building a strong US business, despite Cipla being a late entrant. Hamied said this was made possi...
- Pills to wellness, Cipla is seeking a new identityOne of the major successes of Hamied was building a strong US business, despite Cipla being a late entrant. Hamied said this was possible b...
- ET Businesswoman of the Year 2021: Samina Hamied - The woman who carries forward a storied legacy, seeking profit, but never at the cost of values“I am humbled and honoured to receive the ET’s Businesswoman of the Year Award. This recognition belongs to each and every one of our 25,00...
- Market cap-to-GDP looks comfortable; top five stocks that can surge up to 40%As valuation looks comfortable, market experts believe it is a good time to enter the market at current valuation and reap the benefits of ...
- FDA norms punch a Rs 5,000 crore hole in Pharma IndustryIn FY16, the top five — Sun Pharma, Dr Reddy’s, Lupin, Aurobindo and Cipla — ran up a total bill of Rs 3,497 crore in legal and professiona...
- Even after poor results, Cipla stock may just be the right pick nowThe US business is 20% of total revenues. As the proportion of this high-margin business grows, it will help Cipla improve profitability.
- Five reasons why it may just be the right time to buy Cipla now?For investors looking at value buys of quality stocks from a longer term perspective – Cipla may just be the right pick at this juncture.
- Cipla Q4 disappoints, profit falls 69% to Rs 80.87 croreCipla Ltd, India's fifth-largest drugmaker by sales, reported a fall of 69 per cent in its quarterly earnings on Tuesday, far short of anal...
- Cipla seals Invagen and Exelan deals in USThe deal closure, that involved approvals from the US regulatory agencies, will see Cipla vault its sales from that market to around $400 m...
- PuraCap suit may impact Cipla's $550-million dealIn an email response seeking comment, PuraCap said its complaint was publicly available at the US District Court for the Southern District ...
- Sensex rangebound; Nifty holds 8,100; Bharat Forge slumps 5%, SCI gains 7%The S&P BSE Sensex recouped losses after falling as much as 133 points in opening trade on Wednesday following muted trend seen in other As...
- Twelve stocks in focus in Wednesday's tradeIndian markets are expected to trade in a range. Here is a list of twelve stocks which are likely to remain in focus today.
- Analysts bet on Cipla as acquisitions expected to boost company's growthAcquisitions of two companies in the US will help Cipla increase its foothold in the market and has made analysts bullish on the counter.
- Goal to make US contribute 20% to our business by 2020: Sudhanshu Priyadarshi, CiplaWe have had a good beginning in the US since our ‘go live’ in January 2015 and we expect to continue our growth trajectory there.
- Cipla's ratings unlikely to be impacted by US acquisitions: India RatingsIndia Ratings & Research today said Cipla's ratings are unlikely to be affected by the recent cash-rich acquisitions of two US-based compan...
- Nomura neutral on Cipla, target Rs 689Cipla has acquired a portfolio of largely plain vanilla oral solids where its capabilities are already well-established, and hence the acqu...
- Post Invagen sale, Hetero says to strengthen US operationsCipla said the group, through its subsidiary Camber Pharmaceuticals Inc., will continue to strengthen its operations in the US.
- InvaGen, Exelan acquisition will give Cipla manufacturing plant, R&D base in USCipla on Friday fulfilled a longstanding desire to expand its beachhead in the US by buying Hetero Pharma’s US business for about $550 mill...
- Cipla surges on US acquisitions worth $550 millionCipla shares climbed over 3% in morning trade after the company said its UK-based subsidiary, Cipla EU, will acquire two US-based companies.
Load More
